

Published Date:	Thursday 23rd May, 2019	Publication:	The Financial Express [Bangalore]
Journalist:	Bureau	Page No:	6
MAV/CCM:	9,648/8.04	Circulation:	15,444

### **Canada clears Mylan & Biocon's biosimilar**

BIOTECHNOLOGY MAJOR Biocon and Mylan NV on Wednesday said Canadian health regulator Health Canada has approved Mylan's biosimilar Ogivri co-developed with Biocon, used for the treatment certain breast and stomach cancers. Ogivri is a biosimilar to Hoffmann-La Roche's Herceptin. Mylan plans to launch the product this quarter and anticipates potentially being the first company to offer a trastuzumab biosimilar in Canada, the companies said in a joint statement.